X0306 4 2020-11-02 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001758363 Turtle Cameron C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 Chief Business Officer Common Stock 2020-11-02 4 M 0 5000 13.20 A 75531 D Common Stock 2020-11-02 4 M 0 2500 17.00 A 78031 D Common Stock 2020-11-02 4 S 0 9145 70.4438 D 68886 D Common Stock 2020-11-02 4 S 0 3146 71.4167 D 65740 D Common Stock 2020-11-02 4 S 0 209 72.0961 D 65531 D Stock Option (Right to Buy) 13.20 2020-11-02 4 M 0 5000 0.00 D 2028-11-05 Common Stock 5000 75000 D Stock Option (Right to Buy) 17.00 2020-11-02 4 M 0 2500 0.00 D 2028-06-20 Common Stock 2500 13920 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Represents the weighted average sale price of the shares sold from $69.97 to $70.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 through 4. Represents the weighted average sale price of the shares sold from $70.98 to $71.94 per share. Represents the weighted average sale price of the shares sold from $72.01 to $72.13 per share. 25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. The shares subject to this option vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continuous service to the Issuer through each such vesting date. /s/ Franco Valle, Attorney-in-Fact 2020-11-02